Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Two-Part, Parallel-Group Study to Assess the Bioequivalence of Subcutaneously Administered Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Subjects

NCT07214766 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT07214766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Two-Part, Parallel-Group Study to Assess the Bioequivalence of Subcutaneously Administered Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Subjects
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 17, 2025
Completion date
July 3, 2026
Enrollment
331 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants